echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > CStone Pharmaceuticals announces that China’s first selective RET inhibitor Pugeta® (Platinib Capsules) has been approved, providing new treatment options for lung cancer patients

    CStone Pharmaceuticals announces that China’s first selective RET inhibitor Pugeta® (Platinib Capsules) has been approved, providing new treatment options for lung cancer patients

    • Last Update: 2021-03-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    (Suzhou, China, March 24, 2021) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focused on the development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, today announced that China National The Drug Administration (NMPA) approved Phuket Hua? (Platinib Capsules) As a national first-class new drug, it is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who have previously received platinum-containing chemotherapy for transfection rearrangement (RET) gene fusion positive treatment.


    Dr.


    Professor Wu Yilong from Guangdong Provincial People’s Hospital, the main investigator of the ARROW study, said: “In the field of precision treatment of lung cancer, the research and development of RET targets is a huge breakthrough.


    The ARROW study is a global clinical study aimed at evaluating the safety, tolerability and effectiveness of pratinib in patients with RET fusion-positive NSCLC, RET mutant medullary thyroid carcinoma and other advanced solid tumors with RET fusion.


    Pratinib is a potent and selective RET inhibitor developed by Blueprint Medicines, a partner of CStone Pharmaceuticals.


    About RET fusion-positive non-small cell lung cancer

    About RET fusion-positive non-small cell lung cancer

    The incidence of lung cancer has continued to increase in China in recent years.


    In the field of lung cancer, EGFR, ALK, ROS1 and other driver gene mutations have been widely popularized, and targeted drugs targeting these driver genes have been approved for marketing.


    About Phuket Hua (Platinib Capsules)

    About Phuket Hua (Platinib Capsules)

    Pugeta is an oral, once-a-day, potent and highly selective RET inhibitor.


    The U.


    Pratinib has not been approved for other indications in China or the United States, or medical regulatory agencies in other regions have not made an approval decision for any indication of pratinib.


    Pratinib is designed to selectively and effectively target oncogenic RET mutations, including secondary RET mutations that may lead to treatment resistance.


    Globally, clinical development for pratinib for the treatment of patients with RET fusion-positive NSCLC, various types of thyroid cancer and other solid tumors is ongoing.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.